TABLE 1

Symptoms and quality of life (QoL) assessed during prednisone treatment

Symptom and/or QoL-related questionnairePatientsBaselineMonth 1Month 3#
MRC score182.44±1.041.33±0.91*1.39±0.92*
FAS score1827.4±10.821.0±6.6*20.7±7.6*
SGRQ
 Symptoms1745.0±21.129.7±22.4*27.5±25.1*
 Activity1755.9±24.938.8±27.0*36.8±28.4*
 Impact1728.4±23.518.5±15.718.2±15.1*
 Total1740.2±21.826.5±18.1*25.4±19.1*
SF-36
 PCS1539.0±6.940.2±6.937.4±6.9
 MCS1533.5±6.336.2±7.039.2±8.0*
KSQ
 GHS1161.9±14.572.0±18.2*67.0±15.0
 Lung1059.0±13.570.4±23.170.1±20.2*

Data are presented as n or mean±sd. MRC: Medical Research Council; FAS: Fatigue Assessment Scale; SGRQ: St George's Respiratory Questionnaire; SF-36: Short-Form health survey; PCS: physical component score; MCS: mental component score; KSQ: King's Sarcoidosis Questionnaire; GHS: general health status. #: none of the values are statistically significant at month 3 compared with values at month 1; : p=0.055; *: p<0.05 compared with baseline, using a paired sample t-test.